Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Prostate Cancer Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

118 recruiting trials for Prostate Cancer. Eligibility criteria explained in plain English.

TrialFinderData lists 118 Prostate Cancer clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 2 is the largest group at 35% (19 studies); the largest phase groups are Phase 2: 19, Phase 1 / Phase 2: 11, Phase 1: 10, Phase 3: 8.

Research is led by National Cancer Institute (NCI) (3), University of Florida (3), Mayo Clinic (3), among the most active sponsors registered for these trials.

The most frequently studied intervention is Enzalutamide (drug, 5 trials), followed by Questionnaire Administration, Abiraterone acetate.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
118
Total Trials
118
Recruiting Now
8
Phase 3 Trials
10
Sponsors

Track Prostate Cancer trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT00451022

Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies

This study aims to provide long-term follow-up care of patients previously enrolled in a vaccine study that involved poxviral vectors. Vectors are sequences of genetic material...

Sponsor: National Cancer Institute (NCI)Enrolling: 7501 location
RECRUITINGNCT07436078

Culturally Adapting an Intervention to Increase Genetic Testing in African American Cancer Survivors

The goal of this clinical trial is to culturally adapt an educational genetic counseling intervention to increase the uptake in genetic counseling and testing among African...

Sponsor: Barbara Ann Karmanos Cancer InstituteEnrolling: 851 location
RECRUITINGPhase 1 / Phase 2NCT04585750

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or...

Sponsor: PMV Pharmaceuticals, IncEnrolling: 30020 locations
RECRUITINGNCT06691776

Feasibility of CBCT-Guided Online Adaptive Radiotherapy (FASCINATE)

The accuracy of radiotherapy can be increased by correcting for geometric uncertainties and changes between radiotherapy fractions. These corrections are currently done with...

Sponsor: The Netherlands Cancer InstituteEnrolling: 1001 location
RECRUITINGPhase 3NCT06563388

Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial

This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on...

Sponsor: Roswell Park Cancer InstituteEnrolling: 8001 location
RECRUITINGPhase 3NCT06717711

Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Robot-assisted Surgical Treatment of...

This prospective randomized controlled trial (RCT) is designed to provide high level evidence on the efficacy of Low-intensity Extracorporeal Shock Wave Therapy (Li-ESWT) in the...

Sponsor: Regina Elena Cancer InstituteEnrolling: 1582 locations
RECRUITINGPhase 1NCT06193486

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

This is a phase 1 single center clinical trial for patients with end stage Metastatic Castration Resistant Prostate Cancer who have progressed through standard of care treatment...

Sponsor: H. Lee Moffitt Cancer Center and Research InstituteEnrolling: 301 location
RECRUITINGNCT06209853

Correlation Between PSA Levels and F-18 PSMA PET/CT Findings in Prostate Cancer Patient

It is a cross sectional study aimed to correlate between PSA Levels and F-18 PSMA PET/CT Scan findings and to evaluate the impact of PET/CT findings on the patient management

Sponsor: Assiut UniversityEnrolling: 591 location
RECRUITINGNCT07626151

Electric Cardiometry-Guided Standard Versus Restricted Fluid Therapy In Robotic Prostaectomy

Fluid therapy during surgery is an important factor that is related to long term mortality and morbidity and it's directly related to tissue perfusion as well. The main target in...

Sponsor: Nazmy Edward SeifEnrolling: 901 location
RECRUITINGNCT06465966

UFPTI 2403-PR12: Real-Time Volumetric Ionizing Radiation Acoustic Imaging for In-vivo Proton Treatment Monitoring in...

The purpose of this study is to evaluate the use of ionizing-radiation photo acoustic imaging (iRAI) for proton radiation treatment.

Sponsor: University of FloridaEnrolling: 301 location
RECRUITINGNCT05653063

ARCHERY - Artificial Intelligence Based Radiotherapy Treatment Planning for Cervical, Head and Neck and Prostate Cancer

The aim of this study is to look at whether an Artificial Intelligence (AI) based computer program can automate two components of the radiotherapy treatment pathway to a...

Sponsor: University College, LondonEnrolling: 9906 locations
RECRUITINGNCT06334809

INSIDE: Identification of Genomic Screening Pathways in Cancer Patients With DNA Repair Alterations

400 patients will be enrolled and divided into 3 cohorts: Cohort A: patients with high risk localized prostate cancer (PC) defined as \>cT3 or PSA \> 20 ng/mL or presence of ECE...

Sponsor: Fondazione del Piemonte per l'OncologiaEnrolling: 4002 locations
RECRUITINGNCT06398639

Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer

The goal of this clinical trial is to evaluate a screening method to detect clinically relevant prostate cancer. This clinical trial is using genetic data to determine a man's...

Sponsor: Adam S. Kibel, MDEnrolling: 15005 locations
RECRUITINGPhase 3NCT01492972

Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

The purpose of this study is to compare the effects, good and/or bad of two treatment methods on subjects and their cancer. Proton beam radiation therapy is one of the treatments...

Sponsor: Proton Collaborative GroupEnrolling: 1924 locations
RECRUITINGNCT06982469

High Dose Rate (HDR) Brachytherapy Salvage After Prostatectomy

The goal of this observational study is to learn about the long-term effects of HDR Brachytherapy in men with isolated local relapses after radical prostatectomy. The main...

Sponsor: Clinica Universidad de Navarra, Universidad de NavarraEnrolling: 201 location
RECRUITINGPhase 1 / Phase 2NCT07523529

Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors

This is a multicenter, open-label, Phase 1/2 master protocol evaluating autologous dual-target CAR-T cell therapy in adults with advanced solid cancers. After central biomarker...

Sponsor: Beijing BiotechEnrolling: 721 location
RECRUITINGNCT05001477

Customized TULSA-PRO Ablation Registry

This patient registry will capture data from patients who have been or who are undergoing the transurethral ultrasound ablation (TULSA) procedure as part of their routine clinical...

Sponsor: Profound Medical Inc.Enrolling: 10005 locations
RECRUITINGPhase 2NCT03821246

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

This phase II trial studies how well atezolizumab works alone or in combination with etrumadenant or tocilizumab in treating men with localized prostate cancer before radical...

Sponsor: David OhEnrolling: 682 locations
RECRUITINGNCT05882253

Prostate Cancer IMAGing IN Early Detection (IMAGINED Trial)

The researchers hope to learn if specific types of MRI software and techniques can help improve early prostate cancer detection at time of a MRI-guided prostate biopsy.

Sponsor: University of California, San DiegoEnrolling: 2251 location
RECRUITINGNCT03819751

MRI-targeted Biopsy of the Prostate: Software Versus Visual Registration in the Accuracy of Prostate Cancer Detection

With the general acceptance of MRI and technical advances in biopsy technique of the prostate, new questions arise concerning the selection of patients, the approach, the...

Sponsor: Universitaire Ziekenhuizen KU LeuvenEnrolling: 961 location
RECRUITINGPhase 2NCT04100174

Focal HDR Brachytherapy Boost to Stereotactic Radiotherapy

To determine if fBT+sRT is superior to standard care in terms of urinary toxicity by having fewer patients experience a minimal important decline (MID) in urinary...

Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)Enrolling: 1502 locations
RECRUITINGNCT06429813

Remotely Monitored Exercise Interventions in Patients With mCSPC Undergoing ADT (Prostate 006)

This study consists of two home-based exercise programs: a stationary exercise bicycle intervention (Arm A), and a walking intervention (Arm B). The study will enroll 24 patients...

Sponsor: Paul ViscuseEnrolling: 241 location
RECRUITINGPhase 3NCT06136624

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant...

Sponsor: Merck Sharp & Dohme LLCEnrolling: 131020 locations
RECRUITINGEarly Phase 1NCT05603559

177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer

This is a pilot study to assess the safety and measure image-based absorbed dose of 177Lu-P17-087/177Lu-P17-088 in patients with metastatic castration-resistant prostate cancer...

Sponsor: Peking Union Medical College HospitalEnrolling: 301 location
RECRUITINGNCT06907095

Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals

LEAH is a prospective, observational, single-centre, non-randomised, open-label study of people at increased risk of cancer or malignant disease. The main objective of LEAH is to...

Sponsor: Gustave Roussy, Cancer Campus, Grand ParisEnrolling: 59091 location
RECRUITINGNCT06842264

The Development and Validation of MRI-AI-based Predictive Models for csPCa

This study retrospectively included patients who underwent prostate magnetic resonance imaging (MRI) and subsequent ultrasound-guided prostate biopsy at Peking University First...

Sponsor: Peking University First HospitalEnrolling: 30001 location
RECRUITINGNCT05810467

The Active Surveillance Study

The Active Surveillance study is a prospective study developed to look at the association of biomarkers with PrCa presentation and progression among men on Active Surveillance and...

Sponsor: Institute of Cancer Research, United KingdomEnrolling: 2004 locations
RECRUITINGNCT07541911

A Study to Evaluate the Performance of Confocal Microscopy to Detect Positive Margins During Radical Prostatectomy

The goal of this study is to find out whether a new method called "LaserSAFE" can accurately detect cancer at the edge of the prostate (called a positive margin) during prostate...

Sponsor: University College, LondonEnrolling: 6931 location
RECRUITINGPhase 3NCT07333066

Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus...

This is a phase III, randomized, open-label, multi-center study to assess the efficacy of treatment intensification with docetaxel plus apalutamide and ADT, assessed by event-free...

Sponsor: Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARDEnrolling: 32020 locations
RECRUITINGNCT06762379

Implementation of a New Algorithm for HRR Gene Mutation Testing in Patients With mPC Through Liquid Biopsy Integration

Implementation of a new algorithm for HRR gene mutation testing in patients with mPC through liquid biopsy integration

Sponsor: European Institute of OncologyEnrolling: 1251 location
RECRUITINGPhase 1 / Phase 2NCT03424850

Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy

The purpose of this research study is to learn more about the outcomes and early and late side effects of treating early stage prostate cancer with high dose rate brachytherapy.

Sponsor: Washington University School of MedicineEnrolling: 361 location
RECRUITINGPhase 2NCT07005154

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in...

Sponsor: Astellas Pharma Global Development, Inc.Enrolling: 21820 locations
RECRUITINGPhase 2 / Phase 3NCT06282588

Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers

This Investigator-initiated, Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER) study will be conducted in subjects with...

Sponsor: Cancer Research AntwerpEnrolling: 4939 locations
RECRUITINGPhase 2NCT06568562

XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to determine how well the study drug XL092 is helping to treat a participant's cancer after 16 weeks of treatment. Researchers will also look at how...

Sponsor: University of UtahEnrolling: 321 location
RECRUITINGNCT03830788

Erectile Dysfunction in Good Prognosis Prostate Cancer : Comparison Between Brachytherapy and Stereotactic Body...

The TEMPOS-GEniToUrinary Group (GETUG) study is a multicenter, medico-economic study comparing brachytherapy to SBRT in low and intermediate risk prostate cancer, particularly...

Sponsor: Center Eugene MarquisEnrolling: 24020 locations
RECRUITINGNCT06754488

A Technique Improves Urinary Continence in Patients Undergoing Laparoscopic Radical Prostatectomy

Laparoscopic radical prostatectomy (LRP) is the main treatment method for early prostate cancer, and postoperative urinary incontinence is one of the main complications after LRP....

Sponsor: Suzhou Municipal HospitalEnrolling: 1201 location
RECRUITINGNCT07004582

Lab Research Using Mini-tumors to Study Prostate Cancer Treatments

For men with an aggressive form of prostate cancer, finding the right and effective treatment right away is challenging. Many of these men face a high risk of cancer recurrence:...

Sponsor: Maastricht Radiation OncologyEnrolling: 6003 locations
RECRUITINGPhase 3NCT05019846

SRT Versus SRT+ADT in Prostate Cancer

To clarify the role of short-term Androgen deprivation therapy (ADT) in the context of intermediate unfavorable and a subclass of high-risk patients treated with prostate...

Sponsor: Marco Lorenzo BonuEnrolling: 3101 location
RECRUITINGNCT06536725

Observation of Clinical Consistency of Organoid-chips Drug Sensitivity in Chemotherapy for PCa With Visceral Metastasis

This project plans to establish an organoid chip model of prostate cancer patients with internal organ metastasis from surgical or biopsy tissue sources, and test the sensitivity...

Sponsor: Tianjin Medical University Second HospitalEnrolling: 352 locations
RECRUITINGPhase 2NCT05616650

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

Background: The current standard treatment of prostate cancer is either surgery or radiation. Typically, this includes either the removal or radiation of the whole prostate...

Sponsor: National Cancer Institute (NCI)Enrolling: 421 location
RECRUITINGEarly Phase 1NCT02526368

Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer

This pilot clinical trial studies how well magnetic resonance spectroscopic imaging (MRSI) with hyperpolarized carbon 13 (13C) pyruvate alone or in combination with 13C 15N2 Urea...

Sponsor: Ivan de Kouchkovsky, MDEnrolling: 801 location
RECRUITINGPhase 1 / Phase 2NCT06616155

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

This phase I/II tests the safety, side effects and best dose of ruxolitinib in combination with enzalutamide and how well it works in treating patients with prostate cancer that...

Sponsor: University of Michigan Rogel Cancer CenterEnrolling: 203 locations
RECRUITINGNCT03237026

Predictive and Prognostic Markers for Treatment Outcomes in Prostate Cancer Patients

The study aims to identify potential urine marker metabolites as predictive or prognostic markers for treatment outcomes in patients with prostate cancer.

Sponsor: National Taiwan University HospitalEnrolling: 3601 location
RECRUITINGNCT06820606

Comparing Rezum and Urolift

This is a randomized controlled trial using a non-inferiority design with the subjects randomized 1:1 to either water vapour thermal treatment (REZUM) arm or prostatic urethral...

Sponsor: Chinese University of Hong KongEnrolling: 1201 location
RECRUITINGPhase 3NCT03678025

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants...

Sponsor: SWOG Cancer Research NetworkEnrolling: 127320 locations
RECRUITINGNCT04692675

Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients...

Background: Active surveillance (AS) is a standard approach to treat low and intermediate risk prostate cancer. For AS, disease progression is monitored. AS uses biopsies,...

Sponsor: National Cancer Institute (NCI)Enrolling: 5081 location
RECRUITINGNCT07144228

Validation of a Platelet Proteomic Assay for Diagnosing and Monitoring Prostate Cancer

This is a single center study evaluating whether a new blood test based on platelet proteins rather than plasma proteins can improve detection of prostate cancer and evaluate the...

Sponsor: Duke UniversityEnrolling: 3001 location
RECRUITINGPhase 1NCT07545811

Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy...

Sponsor: Janux TherapeuticsEnrolling: 431 location
RECRUITINGNCT06242509

Intestinal Akkermansia Muciniphila in Prostate Cancer

Prostate cancer has the highest incidence and is the second leading cause of cancer death in men in western countries. Androgen deprivation therapy is the backbone treatment....

Sponsor: Assistance Publique - Hôpitaux de ParisEnrolling: 521 location
RECRUITINGNCT02971085

Seoul National University Prospectively Enrolled Registry for Prostate Cancer With Active Surveillance

In this study, the investigators aim to establish the prostate cancer active surveillance prospective cohort in our institution, and finally investigate the 5 year rates of...

Sponsor: Seoul National University HospitalEnrolling: 4101 location

Showing 50 of 118 trials.Search all Prostate Cancer trials

Frequently Asked Questions

There are currently 118 clinical trials for Prostate Cancer, with 118 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Prostate Cancer, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 8 Phase 3 trials for Prostate Cancer, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.